Dicerna Pharmaceuticals has patented a method using DsiRNA agents to reduce a-1 antitrypsin levels for treating lung diseases in individuals with gene mutations. The method involves introducing specific nucleic acid sequences into cells to decrease target mRNA expression. GlobalData’s report on Dicerna Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Dicerna Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Dicerna Pharmaceuticals, was a key innovation area identified from patents.

Treating lung disease by reducing a-1 antitrypsin levels

Source: United States Patent and Trademark Office (USPTO). Credit: Dicerna Pharmaceuticals Inc

A recently granted patent (Publication Number: US11912996B2) discloses a method for treating lung diseases or disorders in individuals with mutations in the a-1 antitrypsin gene. The method involves introducing a double-stranded nucleic acid (dsNA) into human cells, with the dsNA consisting of two nucleic acid strands, each 21 nucleotides long. One strand has a specific nucleotide sequence (SEQ ID NO:1908) while the other is 100% complementary to it. This dsNA is designed to reduce the expression of a-1 antitrypsin target mRNA in the cells, potentially offering a therapeutic approach for conditions such as emphysema, chronic obstructive pulmonary disease (COPD), and a-1 antitrypsin deficiency.

The patent also details various administration methods for the dsNA, including intravenous, intramuscular, intraperitoneal injections, infusion, subcutaneous injection, transdermal, aerosol, rectal, vaginal, topical, oral, and inhaled delivery. Additionally, the dsNA may contain modified nucleotides, such as 2'-O-methyl nucleotides, 2'-fluoro nucleotides, or a combination of both, along with phosphorothioate linkages. Furthermore, the dsNA can be modified with targeting ligands like GalNAc moieties to enhance its efficacy. The patent covers different configurations and modifications of the dsNA strands, highlighting the potential versatility and customization of this treatment approach for lung diseases associated with a-1 antitrypsin gene mutations.

To know more about GlobalData’s detailed insights on Dicerna Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies